Head-to-head evidence
entacapone vs Opicapone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: COMT · full Parkinson's Disease pipeline
entacapone · Comtess
Marketed by Orion Corporation
NCT00099268 · Phase 3 · completed
The trial was randomized, quadruple-blind, actively controlled, and included 747 participants, with a clinical primary endpoint measuring time to first dyskinesia. However, the reported numerical result favored the comparator, and no p-value or other statistical comparison is provided, so the primary endpoint cannot be classified as definitively met or missed.
Next expected readout: February 2027 · NCT04246437 (registry estimate)
Opicapone · Ongentys
Marketed by Amneal Pharmaceuticals and partners
NCT01568073 · Phase 3 · completed
The study randomized 600 participants and used triple masking with both placebo and entacapone comparator groups. Its primary clinical endpoint was change in daily OFF-time, but the registry reports only group means and no p-value or confidence interval, so whether the primary comparison was statistically successful cannot be determined.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: entacapone's landscape · Opicapone's landscape